LINDA YAUL: Open Payments
NPI 1982484242 · RIDGELAND, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$332 in 16 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $404 · 2025 $332
Food & beverage: $332
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $47 |
| ABIOMED | 1 | $47 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $41 |
| Mallinckrodt Hospital Products Inc. | 2 | $40 |
| GENZYME CORPORATION | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| United Therapeutics Corporation | 1 | $26 |
| Merck Sharp & Dohme LLC | 1 | $17 |
Products named: DUPIXENT, OFEV, ACTHAR, GLASSIA, TEZSPIRE, Tyvaso, ZERBAXA, AIRSUPRA.
Industry payments across MS — which companies pay providers there.
